Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab prophylaxis in severe hemophilia A in Ivory Coast
NCT05279924Completed
- Start
- Jul 2021
- Primary completion
- Oct 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of emicizumab in hemophilia A. Primary endpoints: Annual Bleeding Rate at 12 months, Canadian Haemophilia Outcomes-Kids' Life Assessment Tool at 6 months and 2 more. Started Jul 2021; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT05279924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279924.